Key clinical point: Measuring leptin expression could help differentiate benign renal oncocytomas from chromophobe renal cell carcinoma (RCC).
Major finding: Nuclear leptin intensity was significantly increased for renal oncocytomas versus eosinophilic variants of chromophobe RCC (P = 0.016).
Study details: Evaluation of 75 archived tissue samples, including 30 chromophobe RCC specimens, 15 renal oncocytomas, and 30 clear cell RCCs, along with matched, noncancerous kidney tissue specimens.
Disclosures: The University of Malaya, Kuala Lumpur, Malaysia, funded the study. The authors stated that they had no conflicts of interest.
Gobe G et al. Pathology. 2018 Aug;50(5):504-10
This Week's Must Reads
Federal proposal aims to move doctors back to face-to-face interventions, Office of the National Coordinator for Health IT
Program reduces ER admissions and inpatient costs, Mendenhall M et al. Quality Care Symposium, Abstract 30
Pain severity decreased over time with app, Kamdar MM et al. PallOnc 2018, Abstract 76
National health care spending growth slowed to 3.9% in 2017 , Martin A et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05085
Medicare Part D rules on protected medication classes could change, Federal Register (83 FR 62152)
Must Reads in Genitourinary Cancer
Treating prostate with radiotherapy boosts survival in advanced prostate cancer, Parker C et al. ESMO 2018, Abstract LBA5_PR
Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10
Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.
Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002
Radioactive agent approved for adrenal tumors, FDA approves iobenguane I 131 injection (Azedra) for IV use for the treatment of pheochromocytoma or paraganglioma.